HER2/ErbB2 Monoclonal antibody
HER2/ErbB2 Monoclonal Antibody for IHC, IF-P, ELISA
Host / Isotype
Mouse / IgG2b
Reactivity
human
Applications
IHC, IF-P, ELISA
Conjugate
Unconjugated
CloneNo.
1B12A7
Cat no : 60311-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human breast cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF-P detected in | human breast cancer tissue |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:800-1:3200 |
Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
IHC | See 4 publications below |
IF | See 2 publications below |
Product Information
60311-1-Ig targets HER2/ErbB2 in IHC, IF-P, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Mouse / IgG2b |
Class | Monoclonal |
Type | Antibody |
Immunogen | HER2/ErbB2 fusion protein Ag16463 相同性解析による交差性が予測される生物種 |
Full Name | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
Calculated molecular weight | 1255 aa, 138 kDa |
GenBank accession number | BC156755 |
Gene symbol | HER2/ErbB2 |
Gene ID (NCBI) | 2064 |
RRID | AB_2881423 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
HER2, ErbB2, and Neu is a 185-kDa transmembrane glycoprotein member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for HER2/ErbB2 antibody 60311-1-Ig | Download protocol |
IF protocol for HER2/ErbB2 antibody 60311-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Mol Med Rep HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified. | ||
Oncol Lett Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer. | ||
Mol Cancer CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer | ||
Int J Cancer Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients | ||
Adv Mater Targeted SERS Imaging and Intraoperative Real-Time Elimination of Microscopic Tumors for Improved Breast-Conserving Surgery |